Jeffrey S. Parkin

Array ( [id] => 14893969 [patent_doc_number] => 20190290750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => DNA ANTIBODY CONSTRUCTS FOR USE AGAINST EBOLA VIRUS [patent_app_type] => utility [patent_app_number] => 16/465680 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12728803 [patent_doc_number] => 20180134768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => METHODS AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSION [patent_app_type] => utility [patent_app_number] => 15/818472 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15818472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12526929 [patent_doc_number] => 10005819 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-26 [patent_title] => Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag [patent_app_type] => utility [patent_app_number] => 15/817761 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 52 [patent_no_of_words] => 31892 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15817761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15945953 [patent_doc_number] => 10660854 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-26 [patent_title] => Thermostable vaccines based on ether lipids and native viral envelope proteins [patent_app_type] => utility [patent_app_number] => 15/813706 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 20 [patent_no_of_words] => 15381 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15813706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16695521 [patent_doc_number] => 10946090 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Consensus/ancestral immunogens [patent_app_type] => utility [patent_app_number] => 15/813992 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 178 [patent_figures_cnt] => 302 [patent_no_of_words] => 19279 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15813992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12706963 [patent_doc_number] => 20180127487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => ANTI-CHIKV ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/787647 [patent_app_country] => US [patent_app_date] => 2017-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15787647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15882845 [patent_doc_number] => 10647754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-12 [patent_title] => Stabilized single human CD4 domains and fusion proteins [patent_app_type] => utility [patent_app_number] => 15/784988 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 12106 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15784988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13207147 [patent_doc_number] => 10117924 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-06 [patent_title] => Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions [patent_app_type] => utility [patent_app_number] => 15/783675 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 11 [patent_no_of_words] => 19497 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 327 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15783675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641256 [patent_doc_number] => 20180105583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => ANTIBODIES THAT BIND ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/783655 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15783655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993761 [patent_doc_number] => 20190315838 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => ANTIBODIES THAT BIND ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/341845 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17251154 [patent_doc_number] => 11186626 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop [patent_app_type] => utility [patent_app_number] => 16/340996 [patent_app_country] => US [patent_app_date] => 2017-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 20091 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16340996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16909825 [patent_doc_number] => 11041858 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-22 [patent_title] => Method for the detection of cells associated with the latent HIV viral reservoir using membrane biomarkers [patent_app_type] => utility [patent_app_number] => 16/337003 [patent_app_country] => US [patent_app_date] => 2017-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 30 [patent_no_of_words] => 10795 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14682427 [patent_doc_number] => 20190240328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => NOVEL HUMANIZED ANTI-EBOLA ANTIBODIES USEFUL IN PREVENTING EBOLA INFECTIONS [patent_app_type] => utility [patent_app_number] => 16/335767 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19624102 [patent_doc_number] => 12162906 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Method for preparing multimeric forms of the hepatitis c virus (HCV) envelope glycoprotein 2 (HCV E2) [patent_app_type] => utility [patent_app_number] => 16/337900 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 31 [patent_no_of_words] => 30096 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14246197 [patent_doc_number] => 10273290 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-30 [patent_title] => Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides [patent_app_type] => utility [patent_app_number] => 15/711058 [patent_app_country] => US [patent_app_date] => 2017-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 73 [patent_no_of_words] => 38946 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15711058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14564135 [patent_doc_number] => 20190209674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => COMBINATION OF NOVEL VACCINES AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS [patent_app_type] => utility [patent_app_number] => 16/334441 [patent_app_country] => US [patent_app_date] => 2017-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16334441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16444899 [patent_doc_number] => 10836811 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody [patent_app_type] => utility [patent_app_number] => 15/701679 [patent_app_country] => US [patent_app_date] => 2017-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 109 [patent_figures_cnt] => 92 [patent_no_of_words] => 103758 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15701679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770887 [patent_doc_number] => 10981976 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof [patent_app_type] => utility [patent_app_number] => 16/328521 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 31081 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16328521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339335 [patent_doc_number] => 12049513 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager [patent_app_type] => utility [patent_app_number] => 16/329098 [patent_app_country] => US [patent_app_date] => 2017-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 93 [patent_no_of_words] => 60604 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16329098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293609 [patent_doc_number] => 20190389940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => CONSTRUCTION AND APPLICATION OF RECOMBINANT GENE FOR CHIMERIC ANTIGEN RECEPTOR FOR TREATING HIV INFECTION [patent_app_type] => utility [patent_app_number] => 16/317514 [patent_app_country] => US [patent_app_date] => 2017-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317514 [rel_patent_id] =>[rel_patent_doc_number] =>)